https://scholars.lib.ntu.edu.tw/handle/123456789/580332
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Kang Y.-K. | en_US |
dc.contributor.author | Chen Z. | en_US |
dc.contributor.author | Tsao C.-J. | en_US |
dc.contributor.author | Qin S. | en_US |
dc.contributor.author | Kim J.S. | en_US |
dc.contributor.author | Luo R. | en_US |
dc.contributor.author | Feng J. | en_US |
dc.contributor.author | Ye S. | en_US |
dc.contributor.author | Yang T.-S. | en_US |
dc.contributor.author | Xu J. | en_US |
dc.contributor.author | Sun Y. | en_US |
dc.contributor.author | Liang H. | en_US |
dc.contributor.author | Liu J. | en_US |
dc.contributor.author | Wang J. | en_US |
dc.contributor.author | Tak W.Y. | en_US |
dc.contributor.author | Pan H. | en_US |
dc.contributor.author | Burock K. | en_US |
dc.contributor.author | Zou J. | en_US |
dc.contributor.author | Voliotis D. | en_US |
dc.contributor.author | Guan Z. | en_US |
dc.date.accessioned | 2021-09-01T01:54:24Z | - |
dc.date.available | 2021-09-01T01:54:24Z | - |
dc.date.issued | 2009 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-57749189578&doi=10.1016%2fS1470-2045%2808%2970285-7&partnerID=40&md5=03a2787bcaaed09328feb4aec2398a97 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/580332 | - |
dc.relation.ispartof | The Lancet Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | placebo; sorafenib; adult; advanced cancer; aged; alopecia; anorexia; article; ascites; Asia; China; clinical trial; controlled clinical trial; controlled study; desquamation; diarrhea; disease control; disease course; double blind procedure; drug dose reduction; drug efficacy; drug safety; drug tolerability; drug withdrawal; fatigue; female; hand foot syndrome; human; hypertension; interactive voice response system; liver cell carcinoma; liver dysfunction; liver function; major clinical study; male; medical decision making; multicenter study; multiple cycle treatment; nausea; outcome assessment; overall survival; phase 3 clinical trial; priority journal; randomized controlled trial; rash; South Korea; Taiwan; treatment outcome; upper gastrointestinal bleeding; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyridines | - |
dc.title | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/S1470-2045(08)70285-7 | - |
dc.identifier.pmid | 19095497 | - |
dc.identifier.scopus | 2-s2.0-57749189578 | - |
dc.relation.pages | 25-34 | - |
dc.relation.journalvolume | 10 | - |
dc.relation.journalissue | 1 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。